July -
- Net sales:
SEK 6.2 million (8.8) -
Operating income:
SEK -5.4 million (-0.8) -
Net income for the period:
SEK -5.5 million (-0.8) -
Earnings per share:
SEK -0.07 (-0.01)
January -
- Net sales:
SEK 22.3 million (26.8) -
Operating income:
SEK -13.6 million (-6.5) -
Net income for the period:
SEK -13.7 million (-6.6) -
Earnings per share:
SEK -0.19 (-0.09)
Summary of the quarter
- The number of units sold decreased by 13%, and the turnover decreased by 30% due to weaker sales to some of our major European markets, including
Germany ,Sweden , andSpain . -
The most notable sales growth (in terms of units sold) was observed in
India , with a remarkable 120% increase compared to the same period in 2022. - Training and start-up of Glycosorb® ABO at ten new transplant centers in four countries, including two liver transplant centers.
-
A milestone was achieved with the first blood group incompatible kidney transplantation using Glycosorb® ABO in
Lithuania . -
The company participated at the
European Society of Transplantation inAthens in September. - The recruitment process for a Business Development Manager in the Transfusion business area was successfully concluded.
CEO comment
"As the newly appointed acting CEO, I would like to begin by addressing the financial challenges highlighted in the press release on
By the end of September, our cash reserves had decreased by over
A significant and general adjustment of our product prices would be a natural measure in this regard. However, it's important to bear in mind that healthcare units dealing with apheresis products, including ours, often receive inadequate or unfavorable compensation for extracorporeal blood treatments. This poses a challenge in several of our key markets. Price adjustments will be necessary, but they become a delicate matter, requiring well-planned considerations in the complex and competitive environment we navigate.
We are determined to adapt to the current situation and position ourselves for long-term success.
The CEO and the new board agree that the company is now strengthening its focus on the launch of our product within the transfusion area.
An important step in this direction was the appointment, in October, of a completely new position for the company: Business Development Manager, Transfusion. It is the first time the company has a dedicated function to drive and commercialize this exciting area. As we know, the product has many interesting application areas. In addition to plasma, whole blood, and platelets, the product may also be of interest for the treatment of stem cells and rare blood groups. Furthermore, we will also evaluate possible collaborations.
Excellent results have been presented at conferences in
I am delighted to work with everyone here at
-
For more information, please contact:
Email: johan.nilsson@glycorex.com, Tel: +46 46 286 5230
This information is the kind of information
Brief information about the company
Glycosorb® ABO is one of the company's self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplantation by specifically reducing anti-A/B antibodies in the organ recipient's plasma. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific papers have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Glycosorb® ABO has been used in more than 6,000 transplants in over 25 countries. In addition to
The company has also developed a CE-marked medical device product for the production of universal (low titer) blood products and is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.
https://news.cision.com/glycorex-transplantation/r/glycorex-transplantation-ab--publ--interim-report-january---september-2023,c3884564
https://mb.cision.com/Main/15286/3884564/2461336.pdf
(c) 2023 Cision. All rights reserved., source